Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Acta Pharmacologica Sinica

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1745-7254.2006.00251.xPMID 16364207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production.

  2005cited by this paper
• Cholinesterase Inhibitors in the Treatment of Dementia

  2005cited by this paper
• A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

  2005cited by this paper
• Investigations of linker structure on the potency of a series of bidentate protein tyrosine phosphatase inhibitors.

  2005cited by this paper
• Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.

  2005cited by this paper
• Ion-pair reverse-phase high performance liquid chromatography method for determination of Huperzine-A in beagle dog serum.

  2005cited by this paper
• Formylchromone derivatives as irreversible and selective inhibitors of human protein tyrosine phosphatase 1B. Kinetic and modeling studies.

  2005cited by this paper
• Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors.

  2005cited by this paper
• Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells

  2005cited by this paper
• Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.

  2004cited by this paper
• Effects of huperzine A on [Ca~(2+)]_i level and expression of CaM ,CaMPKII mRNA in hippocampal neurons of mice with vascular dementia

  2004cited by this paper
• Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.

  2004cited by this paper
• Regulation of Nicotinic Acetylcholine Receptor Channel Function by Acetylcholinesterase Inhibitors in Rat Hippocampal CA1 Interneurons

  2004cited by this paper
• Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.

  2004cited by this paper
• Discovery of novel PTP1b inhibitors.

  2004cited by this paper
• Liquid chromatographic-tandem mass spectrometric method for the quantitation of huperzine A in dog plasma.

  2004cited by this paper
• Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells.

  2004cited by this paper
• Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.

  2004cited by this paper
• Protective effect of tetramethylpyrazine on learning and memory function in D-galactose-lesioned mice.

  2004cited by this paper
• Effects of huperzine A on liver cytochrome P-450 in rats.

  2003cited by this paper
• Crystal Structure of PTP1B Complexed with a Potent and Selective Bidentate Inhibitor*

  2003cited by this paper
• Classification of Inhibitors of Protein Tyrosine Phosphatase 1B Using Molecular Structure Based Descriptors

  2003cited by this paper
• Huperzine-A capsule in treatment of age-associated memory impairment with a double-blind study

  2003cited by this paper
• PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity

  2003cited by this paper
• Acute effects of huperzine A and tacrine on rat liver.

  2003cited by this paper
• Antioxidant treatment in alzheimer’s disease

  2003cited by this paper
• Mitochondrial permeability transition: a common pathway to necrosis and apoptosis.

  2003cited by this paper
• Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A.

  2003cited by this paper
• Potentiation of Acetylcholine Action by Huperzine-A and Physostigmine on Some Vertebrate Effectors, Including Human Iris Sphincter Muscle

  2003cited by this paper
• The Cholinesterase Inhibitors

  2003cited by this paper
• Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons.

  2003cited by this paper
• A clinical study of huperzine A on mild and moderate traumatic brain injury in memory and cognitive impairment

  2002cited by this paper
• Pilot trial of huperzine A to treat child language delay

  2002cited by this paper
• Protein tyrosine phosphatase 1B inhibitors for diabetes

  2002cited by this paper
• X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement.

  2002cited by this paper
• Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia.

  2002cited by this paper
• Huperzine A attenuates apoptosis and mitochondria‐dependent caspase‐3 in rat cortical neurons

  2002cited by this paper
• Review of the value of huperzine as pretreatment of organophosphate poisoning.

  2002cited by this paper
• A Clinical Study of the Effect of Huperzine A to Improve the Ability of Verbal Recall, Retention and Repetition in Middle-aged and Elderly Patients with Dysmnesia

  2002cited by this paper
• Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice.

  2002cited by this paper
• [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].

  2002cited by this paper
• Recent discovery and development of protein tyrosine phosphatase inhibitors

  2002cited by this paper
• The permeability transition pore complex: another view.

  2002cited by this paper
• Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex.

  2002cited by this paper
• Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.

  2002cited by this paper
• Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons.

  2002cited by this paper
• Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons.

  2002cited by this paper
• Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by a Coptidis Rhizoma Extract and Protoberberine Alkaloids

  2002cited by this paper
• Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.

  2002cited by this paper
• SUBCHRONIC ADMINISTRATION OF PYRIDOSTIGMINE OR HUPERZINE TO PRIMATES: COMPARED EFFICACY AGAINST SOMAN TOXICITY

  2002cited by this paper
• Huperzine A attenuates amyloid β‐peptide fragment 25‐35‐induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase‐3 activation

  2002cited by this paper
• A study of the efficacy of Huporzine A in the treatment of memory deficiency and recognition decline of cerebral organic disease.

  2001cited by this paper
• The mitochondrion in apoptosis: how Pandora's box opens

  2001cited by this paper
• Huperzine A protects rat pheochromocytoma cells against oxygen–glucose deprivation

  2001cited by this paper
• Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys.

  2001cited by this paper
• The NMDA receptor ion channel: a site for binding of huperzine A

  2001cited by this paper
• Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons.

  2001cited by this paper
• Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat.

  2001cited by this paper
• Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils.

  2001cited by this paper
• Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.

  2001cited by this paper
• Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics.

  2001cited by this paper
• Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation.

  2001cited by this paper
• Acquisition of a Specific and Potent PTP1B Inhibitor from a Novel Combinatorial Library and Screening Procedure*

  2001cited by this paper
• Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells

  2001cited by this paper
• Effects of Huperzine used as pre-treatment against soman-induced seizures.

  2001cited by this paper
• Huperzine A capsules vs tablets in treating senile amnesia: a double-blind study

  2000cited by this paper
• Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury.

  2000cited by this paper
• Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats.

  2000cited by this paper
• Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.

  2000cited by this paper
• Molecular dynamics simulations of protein-tyrosine phosphatase 1B. II. substrate-enzyme interactions and dynamics.

  2000cited by this paper
• Apoptosis in the nervous system

  2000cited by this paper
• Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance.

  2000cited by this paper
• Impairment of hippocampal long‐term potentiation by Alzheimer amyloid β‐peptides

  2000cited by this paper
• Protective effects of huperzine A on β-amyloid25-35 induced oxidative injury in rat pheochromocytoma cells

  2000cited by this paper
• Chapter 21. Protein tyrosine phosphatase inhibition

  2000cited by this paper
• Similar potency of the enantiomers of huperzine A in inhibition of [(3)H]dizocilpine (MK-801) binding in rat cerebral cortex.

  2000cited by this paper
• Huperzine A reverses scopolamine- and muscimol-induced memory deficits in chick.

  2000cited by this paper
• Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides.

  2000cited by this paper
• Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance.

  2000cited by this paper
• Huperzine A capsules vs tablets in treatment of Alzheimer disease: multicenter studies

  2000cited by this paper
• Huperzine A and tacrine attenuate β‐amyloid peptide‐induced oxidative injury

  2000cited by this paper
• Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats.

  1999cited by this paper
• [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases.

  1999cited by this paper
• Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment.

  1999cited by this paper
• Molecular dynamics simulations of protein-tyrosine phosphatase 1B. I. ligand-induced changes in the protein motions.

  1999cited by this paper
• Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism.

  1999cited by this paper
• Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.

  1999cited by this paper
• Elevated oxidative stress in models of normal brain aging and Alzheimer's disease.

  1999cited by this paper
• Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.

  1999cited by this paper
• Modulation of NMDA receptor by huperzine A in rat cerebral cortex.

  1999cited by this paper
• Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B.

  1999cited by this paper
• Suppressive action produced by β-amyloid peptide fragment 31–35 on long-term potentiation in rat hippocampus is N-methyl-d-aspartate receptor-independent: it's offset by (−)huperzine A

  1999cited by this paper
• Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.

  1999cited by this paper
• The changing landscape of ischaemic brain injury mechanisms

  1999cited by this paper
• Cholinesterases in neural development: new findings and toxicologic implications.

  1999cited by this paper
• Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury.

  1999cited by this paper
• Pathobiology of ischaemic stroke: an integrated view.

  1999cited by this paper
• Presenilins upregulate functional K+ channel currents in mammalian cells.

  1998cited by this paper
• Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper

• Nanovesicles from Rosa canina: A Treasure Trove of Antioxidant Potential for Oxidative Stress, Inflammation, and Gut Microbiota Modulation

  2025cites this paper
• Antioxidant Natural Compounds Integrated with Targeted Protein Degradation: A Multi-Modal Strategy for Alzheimer’s Disease Therapy

  2025cites this paper
• The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories

  2025cites this paper
• Neuroprotective effects of Gastrodia elata and its compounds in a Caenorhabditis elegans Alzheimer's disease model.

  2025cites this paper
• Six-membered N-heterocyclic alkaloids as ChE inhibitors in alzheimer’s disease treatment

  2025cites this paper
• A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management

  2025cites this paper
• The association of the Wnt/β-catenin signaling pathway with Alzheimer's disease.

  2025cites this paper
• Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

  2025cites this paper
• Phyllosphere mycobiome in two Lycopodiaceae plant species: unraveling potential HupA-producing fungi and fungal interactions

  2025cites this paper
• Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer’s disease

  2025cites this paper
• Biotechnological approaches for the production of neuroactive huperzine A.

  2025cites this paper
• Reevaluating Alzheimer's disease treatment: Can phytochemicals bridge the therapeutic Gap?

  2025cites this paper
• Return to Spontaneous Circulation in a Patient With Cholinergic Syndrome at the Emergency Department of Buea Regional Hospital, Cameroon

  2025cites this paper
• Post stroke depression: pathogenesis and molecular mechanisms of natural product-based interventions

  2025cites this paper
• Inhibition of CRMP2 Phosphorylation Suppresses Microglia Activation in the Retina and Optic Nerve and Promotes Optic Nerve Regeneration After Optic Nerve Injury

  2024cites this paper
• Recent advancements in the role of phytochemicals and medicinal plants in prophylaxis and management of Alzheimer’s disease

  2024cites this paper
• Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate)-based microspheres as a sustained platform for Huperzine A delivery for alzheimer's disease therapy.

  2024cites this paper
• Physico-Chemical Study of the Anti-Diabetic Drug of [BzN-EJJ-amide] for Treatment Type2 Diabetes Using CNT Sensor by Drug Delivery Method

  2024cites this paper
• Alkaloids as drug leads in Alzheimer's treatment: Mechanistic and therapeutic insights.

  2024cites this paper
• An in silico analysis of the interaction of marine sponge-derived bioactive compounds with type 2 diabetes mellitus targets DPP-4 and PTP1B

  2024cites this paper
• Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination

  2024cites this paper
• Effect of bioactive extracts from Eucalyptus globulus leaves in experimental models of Alzheimer's disease.

  2024cites this paper
• The Chemistry and Biology of Lycopodium Alkaloids

  2024cites this paper
• Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

  2023cites this paper
• A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease

  2023cites this paper
• PRODUCTION OF HUPERZINE A BY FUNGAL ENDOPHYTES ASSOCIATED WITH HUPERZIACEAE PLANTS

  2023cites this paper
• Anti-neuroinflammatory effects of alkaloid-enriched extract from Huperzia serrata on lipopolysaccharide-stimulated BV-2 microglial cells

  2023influential citation
• Vagus nerve SARS‐CoV‐2 infection and inflammatory reflex dysfunction: Is there a causal relationship?

  2023cites this paper
• Overcoming challenges in dermal and transdermal delivery of herbal therapeutics with polymeric microneedles

  2023cites this paper
• Insights into the Pathophysiology of Alzheimer’s Disease and Potential Therapeutic Targets: A Current Perspective

  2022cites this paper
• Bacterial Reverse Mutation Test of Verbenalin

  2022cites this paper
• Muscarinic receptors in the rat ovary are involved in follicular development but not in steroid secretion

  2022cites this paper
• Enantioselective Total Synthesis of (+)-Sieboldine A and Analogues Thereof.

  2022cites this paper
• Mass spectrometry imaging: new eyes on natural products for drug research and development

  2022cites this paper
• A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis

  2022cites this paper
• A closer look at the mycobiome in Alzheimer's disease: Fungal species, pathogenesis and transmission

  2022cites this paper
• Dietary and nutraceutical-based therapeutic approaches to combat the pathogenesis of Huntington’s disease

  2022cites this paper
• Pomegranate (Punica granatum L.) Attenuates Neuroinflammation Involved in Neurodegenerative Diseases

  2022cites this paper
• Protective effect of huperzine A against isoproterenol-induced myocardial damage in rats via regulation of PI3K/Akt signaling pathway

  2022cites this paper
• Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update

  2022cites this paper
• Disease-Modifying Activity of Huperzine A on Alzheimer’s Disease: Evidence from Preclinical Studies on Rodent Models

  2022cites this paper
• Discovery of New 1,3,4-Oxadiazoles with Dual Activity Targeting the Cholinergic Pathway as Effective Anti-Alzheimer Agents.

  2022cites this paper
• Study on the Comparative Efficacy and Safety of Intellan, Poly Herbal Product (Test Group) with Vinpocetine (Control Group) to Treat Dementia

  2022cites this paper
• Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors

  2022cites this paper
• Regulation of acetylcholinesterase during the lipopolysaccharide‐induced inflammatory responses in microglial cells

  2022cites this paper
• Medicinal pteridophytes: ethnopharmacological, phytochemical, and clinical attributes

  2022cites this paper
• Hollow urchin-shaped manganese dioxide microspheres immobilized acetylcholinesterase for rapid screening inhibitors from traditional herbal medicines.

  2022cites this paper
• UHPLC-HRMS study of pharmacokinetics of a novel hybrid cholinesterase inhibitor K1234: A comparison between in silico, in vitro and in vivo data.

  2022cites this paper
• Phytopharmacology of herbal biomolecules

  2022cites this paper
• Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy

  2021cites this paper
• Hydrocarbon Potential of the Late Permian and the Late Triassic Source Rocks from the Qamdo (Changdu) Basin, Eastern Tibet and Its Linkage with the Sea Level Change

  2021cites this paper
• The role of the cholinergic anti‐inflammatory pathway in autoimmune rheumatic diseases

  2021cites this paper
• Nanodelivery systems for Alzheimer’s disease: Prospects of natural therapeutic agents

  2021cites this paper
• Inflammation neuroscience: neuro‐immune crosstalk and interfaces

  2021cites this paper
• Huperzia serrata Extract ‘NSP01’ With Neuroprotective Effects-Potential Synergies of Huperzine A and Polyphenols

  2021cites this paper
• The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

  2021cites this paper
• Pd-Catalyzed Direct Diversification of Natural Anti-Alzheimer's Disease Drug: Synthesis and Biological Evaluation of N-Aryl Huperzine A Analogues.

  2021cites this paper
• Huperzine A protects against traumatic brain injury through anti-oxidative effects via the Nrf2-ARE pathway

  2021cites this paper
• Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer’s disease

  2021cites this paper
• Neuroprotective role of Diosgenin, a NGF stimulator, against Aβ (1–42) induced neurotoxicity in animal model of Alzheimer’s disease

  2021cites this paper
• ‘An Apple a Day’?: Psychiatrists, Psychologists and Psychotherapists Report Poor Literacy for Nutritional Medicine: International Survey Spanning 52 Countries

  2021cites this paper
• Optimization of Pressurized Liquid Extraction of Lycopodiaceae Alkaloids Obtained from Two Lycopodium Species

  2021cites this paper
• Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.

  2021cites this paper
• Simultaneous separation and determination of three huperzine alkaloids in Huperzia serrata and its preparations by cyclodextrin-modified mixed micellar electrokinetic capillary chromatography.

  2021cites this paper
• Microbial Endophytes: New Direction to Natural Sources

  2021cites this paper
• Endophytic Fungal Community of Huperzia serrata: Diversity and Relevance to the Production of Huperzine A by the Plant Host

  2021cites this paper
• A Novel PTP1B Inhibitor-Phosphate of Polymannuronic Acid Ameliorates Insulin Resistance by Regulating IRS-1/Akt Signaling

  2021cites this paper
• In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer’s Disease

  2021cites this paper
• Role of Medicinal Plants for the Treatment of Alzheimer’s Disease

  2021cites this paper
• Strategies for the potential treatment of neurological disorders with Chinese and Indian medicinal plants

  2021cites this paper
• A comprehensive review on medicinal herbs and novel formulations for the prevention of Alzheimer's disease.

  2021cites this paper
• Choline-Based Multi-Ingredient Supplementation Can Improve Explosive Strength during a Fatiguing Task

  2021cites this paper
• Adjunctive multi-session transcranial direct current stimulation for neurocognitive dysfunction in schizophrenia: A meta-analysis.

  2021cites this paper
• New and potent production platform of the acetylcholinesterase inhibitor huperzine A by gamma-irradiated Alternaria brassicae under solid-state fermentation

  2021cites this paper
• Effects of the Hydroethanolic Extract of Lycopodium selago L. on Scopolamine-Induced Memory Deficits in Zebrafish

  2021cites this paper
• Effect of continuous and multi-phasic current profiles on the iontophoretic transport of pramipexole, rasagiline and huperzine A: Depicting temporal variation and biodistribution in the skin.

  2021cites this paper
• High-performance liquid chromatographic profile and 1H quantitative nuclear magnetic resonance analyses for quality control of a Xinjiang licorice extract

  2020cites this paper
• Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease

  2020cites this paper
• Shenqi Yizhi granules protect hippocampus of AD transgenic mice by modulating on multiple pathogenesis processes.

  2020cites this paper
• Neuroprotective Effect of Bambusa arundinaceae Leaves Extract on Learning and Memory Impairment in Mice: Impact on NR2B, NR1 and GAP Pathways

  2020cites this paper
• Perioperative Dexmedetomidine Improves Outcomes of Kidney Transplant

  2020cites this paper
• Typical Soft–Sediment Deformation Structures Induced by Freeze/Thaw Cycles: A Case Study of Quaternary Alluvial Deposits in the Northern Qiangtang Basin, Tibetan Plateau

  2020cites this paper
• Anti-dementia Medications: Specific Agents

  2020cites this paper
• Huperzine A and Huperzine B Production by Prothallus Cultures of Huperzia selago (L.) Bernh. ex Schrank et Mart

  2020cites this paper
• Microbial acetylcholinesterase inhibitors for Alzheimer’s therapy: recent trends on extraction, detection, irradiation-assisted production improvement and nano-structured drug delivery

  2020cites this paper
• The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro

  2020cites this paper
• Acetylcholinesterase Sensor Based on Polyelectrolyte Complexes with DNA Inclusion for the Determination of Reversible Inhibitors

  2020cites this paper
• Effects of huperzine A on hippocampal inflammatory response and neurotrophic factors in aged rats after anesthesia

  2020cites this paper
• Antioxidant therapy, oxidative stress, and blood-brain barrier: The road of dietary antioxidants

  2020cites this paper
• Electrochemical Biosensor Based on Polyelectrolyte Complexes with Dendrimer for the Determination of Reversible Inhibitors of Acetylcholinesterase

  2020cites this paper
• Effects of Pre-Workout Multi-Ingredient Supplement on Anaerobic Performance: Randomized Double-Blind Crossover Study

  2020cites this paper
• Huperzine‐A administration recovers rat ovary function after sympathetic stress

  2020cites this paper
• Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy

  2020cites this paper
• Role of the cutaneous extraneuronal cholinergic system in the pathogenesis of psoriasis: a case–control study

  2020cites this paper
• Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling

  2020cites this paper
• The Effectiveness of Acupuncture Treatment for Patients with Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Trials

  2020cites this paper
• Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect

  2020cites this paper
• Structure-Activity relationship of MDSA and its derivatives against Staphylococcus aureus Ser/Thr phosphatase Stp1

  2020cites this paper
• Alzheimer’s Disease: Neurotransmitters Involved and the Possible New Strategies

  2019cites this paper
• Production of Cholinesterase-Inhibiting Compounds in In Vitro Cultures of Club Mosses

  2019cites this paper